

## **Medical Policy:**

# High Frequency Chest Wall Oscillation Devices and Intrapulmonary Percussive Ventilators

POLICY NUMBER	LAST REVIEW
MG.MM.DM.09cC4	September 8, 2023

#### Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as "EmblemHealth"), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### **Definition**

A high frequency chest wall oscillation device (HFCWOD) is an airway clearance device consisting of an inflatable vest connected by tubes to a small air-pulse generator.

#### Guideline

Members are eligible for coverage of an HFCWOD when any of the following conditions/diagnoses are applicable:

- 1. Acid maltase deficiency
- 2. Amyotrophic lateral sclerosis
- 3. Anterior horn cell diseases
- 4. Bronchiectasis
- 5. Cystic fibrosis
- 6. Hereditary muscular dystrophy
- 7. Multiple sclerosis
- 8. Myotonic disorders
- 9. Other myopathies

- 10. Paralysis of the diaphragm
- 11. Post-polio
- 12. Quadriplegia
- 13. Any neuromuscular disease disorder with ineffective cough
- 14. Members with a gastrostomy tube and risk of aspiration if manual chest physical therapy (PT) is indicated on a case by case basis when other methods of daily chest PT have been tried and failed

Well-documented failure of standard treatments to adequately mobilize retained secretions must be made available to the Plan upon request.

## **Limitations/Exclusions**

High frequency chest wall oscillation devices are not covered for any conditions other than those listed above. Intrapulmonary percussive ventilators (IPV) (e.g., the Impulsator F00012) are considered experimental and investigational for all indications due to insufficient evidence of therapeutic value (including but not limited to bronchiectasis, chronic obstructive pulmonary disease [COPD], cystic fibrosis, neuromuscular conditions associated with retained airway secretions or atelectasis, and post-operative pulmonary complications).

## **Procedure Codes**

A7025	High frequency chest wall oscillation system vest, replacement for use with patient owned equipment, each	
A7026	High frequency chest wall oscillation system hose, replacement for use with patient owned equipment, each	
E0467	Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions	
E0483	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each	
94669	Mechanical chest wall oscillation to facilitate lung function, per session	

## **Diagnosis Codes**

A15.0	Tuberculosis of lung	
B91	Sequelae of poliomyelitis	
D81.810	Biotinidase deficiency	
D84.1	Defects in the complement system	
E84.0	Cystic fibrosis with pulmonary manifestations	
E84.11	Meconium ileus in cystic fibrosis	
G12.0	Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]	
G12.1	Other inherited spinal muscular atrophy	
G12.20	Motor neuron disease, unspecified	
G12.21	Amyotrophic lateral sclerosis	
G12.22	Progressive bulbar palsy	

G12.23	Primary lateral sclerosis			
G12.24	Familial motor neuron disease			
G12.25	Progressive spinal muscle atrophy			
G12.29	Other motor neuron disease			
G12.8	Other spinal muscular atrophies and related syndromes			
G12.9	Spinal muscular atrophy, unspecified			
G14	Postpolio syndrome			
G35	Multiple sclerosis			
<del>G71.0</del>	Muscular dystrophy (incomplete code as of 10/01/2018)			
G71.00	Muscular dystrophy, unspecified			
G71.01	Duchenne or Becker muscular dystrophy			
G71.02	Facioscapulohumeral muscular dystrophy			
G71.03	Limb girdle muscular dystrophies			
G71.031	Autosomal dominant limb girdle muscular dystrophy			
G71.032	Autosomal recessive limb girdle muscular dystrophy due to calpain-3 dysfunction			
G71.033	Limb girdle muscular dystrophy due to dysferlin dysfunction			
G71.034	Limb girdle muscular dystrophy due to sarcoglycan dysfunction			
G71.0340	Limb girdle muscular dystrophy due to sarcoglycan dysfunction, unspecified			
G71.0341	Limb girdle muscular dystrophy due to alpha sarcoglycan dysfunction			
G71.0342	Limb girdle muscular dystrophy due to beta sarcoglycan dysfunction			
G71.0349	Limb girdle muscular dystrophy due to other sarcoglycan dysfunction			
G71.035	Limb girdle muscular dystrophy due to anoctamin-5 dysfunction			
G71.038	Other limb girdle muscular dystrophy			
G71.039	Limb girdle muscular dystrophy, unspecified			
G71.09	Other specified muscular dystrophies			
G71.11	Myotonic muscular dystrophy			
G71.12	Myotonia congenita			
G71.13	Myotonic chondrodystrophy			
G71.14	Drug induced myotonia			
G71.19	Other specified myotonic disorders			
G71.2	Congenital myopathies			
G71.3	Mitochondrial myopathy, not elsewhere classified			
G71.8	Other primary disorders of muscles			
G72.0	Drug-induced myopathy			
G72.1	Alcoholic myopathy			
G72.2	Myopathy due to other toxic agents			

G72.89	Other specified myopathies		
G73.7	Myopathy in diseases classified elsewhere		
G82.50	Quadriplegia, unspecified		
G82.51	Quadriplegia, C1-C4 complete		
G82.52	Quadriplegia, C1-C4 incomplete		
G82.53	Quadriplegia, C5-C7 complete		
G82.54	Quadriplegia, C5-C7 incomplete		
J47.0	Bronchiectasis with acute lower respiratory infection		
J47.1	Bronchiectasis with (acute) exacerbation		
J47.9	Bronchiectasis, uncomplicated		
J98.6	Disorders of diaphragm		
M33.02	Juvenile dermatomyositis with myopathy		
M33.12	Other dermatomyositis with myopathy		
M33.22	Polymyositis with myopathy		
M33.92	Dermatopolymyositis, unspecified with myopathy		
M34.82	Systemic sclerosis with myopathy		
M35.03	Sicca syndrome with myopathy		
Q33.4	Congenital bronchiectasis		

## References

Centers for Medicare and Medicaid Services. National Coverage Determination for Intrapulmonary Percussive Ventilator. July 1997. Available at: <a href="http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=229&ncdver=1&DocID=240.5&ncd\_id=240.5&ncd\_version=1&basket=ncd%25253A240%25252E5%25253A1%25253AIntrapulmonary+Percussive+Ventilator+%252528IPV%252529&bc=gAAAAAgAAAAA&. Accessed September 15, 2023.

Deakins K, Chatburn RL. A comparison of intrapulmonary percussive ventilation and conventional chest physiotherapy for the treatment of atelectasis in the pediatric patient. Respir Care. 2002; 47(10):1162-1167.

Irwin RS, Baumann MH, Bolser DC, et al.; American College of Chest Physicians (ACCP). Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(1 Suppl):1S-23S.

Noridian. LCD for High Frequency Chest Wall Oscillation Devices. January 2020. <a href="https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33785&ver=34&keywordtype=starts&keyword=high%20frequenc&bc=0.">https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33785&ver=34&keywordtype=starts&keyword=high%20frequenc&bc=0.</a> Accessed September 15, 2023.

Specialty-matched clinical peer review.

Varekojis SM, Douce FH, Flucke RL, et al. A comparison of the therapeutic effectiveness of and preference for postural drainage and percussion, intrapulmonary percussive ventilation, and high-frequency chest wall compression in hospitalized cystic fibrosis patients. Respir Care. 2003; 48(1):24-28.

# **Revision History**

Company(ies)	DATE	REVISION
EmblemHealth ConnectiCare	Sept. 13, 2019	<ul> <li>Added the following covered indications to HFDWOD:</li> <li>Any neuromuscular disease disorder with ineffective cough</li> <li>Members with a gastrostomy tube and risk of aspiration if manual chest physical therapy (PT) is indicated on a case by case basis when other methods of daily chest PT have been tried and failed</li> </ul>
ConnectiCare	Jun. 14, 2019	ConnectiCare adopts the clinical criteria of its parent corporation EmblemHealth
EmblemHealth	Jun. 10, 2016	Communicated noncoverage of IPVs